A CORUÑA, Spain
- Oct. 14, 2021
-- ARJUNA Therapeutics announces the appointment of Mr Jo Williamson as Chief Patient Representative, and advisor to the Scientific Advisory Board (SAB). Mr Williamson has a distinguished record as patient advocate and founder of the UK Phaeo and Para Cancer Charity to raise awareness and funding of cancers caused by mutations in the SDH-B gene, which leads to paraganglionoma and phaeochromocytoma.
Dr Ross Breckenridge PhD FRCP, CEO of ARJUNA Therapeutics said "We are delighted that Jo has agreed to join ARJUNA as patient representative. He will help us focus our efforts on the daily needs of cancer patients and their families. This is an important moment for us as we move our lead medicine towards the clinic-our focus continues to be on producing medicines with efficacy against currently untreatable cancer that allow as near normal quality of life as possible. We believe that involving patients and their families early in drug development will have benefits for our patients and therefore our company".
Mr Williamson said:
"I am delighted and honoured to have been asked to join the ARJUNA Therapeutics Scientific Advisory Board as a patient representative. I believe that the voice of the patient is essential as science continues to advance. I look forward to this very important role and hopes that my experience with The Phaeo and Para Cancer Charity will help Arjuna Therapeutics focus on the patient and their family."
Background: ARJUNA Therapeutics is a Europe-based early-stage oncology company developing a completely novel platform of small molecule medicines, initially focused on oncology indications. The first molecule in ARJUNA's pipeline, Ag5, is a pan-tumour targeted therapy that crosses the blood-brain-
barrier directed at tumours with mitochondrial dysfunction - a very large group of untreatable cancers characterized by KRAS mutations or other biomarkers, and glioblastoma multiforme.